Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDACAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback